Table 3.
Transplant conditions
| Transplant Condition Evaluated |
Stable Take Rate By Patient Populationa |
Number Of PDX Made By Subtype |
Take Rate By Clinical Subtype (Percent) |
||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Institution | Tissue Type | Host Mouse Strain |
Estradiol Used? |
Immortalized Human Fibroblasts? |
Matrigel/ Cultrex? |
Fragment (F) or Dissociated (D) Cells |
Tissue Previously Cryo- preserved? |
Transplant Location |
Patients Attempted |
Total Patients Yielding A PDX Line |
Overall Take Rate (Percent) |
ER+ (Including HER2+) |
HER2+ Only | "Triple Negative" |
ER+ (Including HER2+) |
HER2+ Only | "Triple Negative" |
References | |
| Baylor College of Medicine | PT | NSG | Pellet | No | No | F | No | CFP | 32 | 6 | 18.8 | 1 | 1 | 4 | 6 | 20 | 36 | Zhang et al (2013) Cancer Res. 4885–4897 | |
| PT | SCID/Bg | Pellet | No | No | F | No | CFP | 70 | 15 | 21.4 | 1 | 2 | 12 | 2 | 40 | 54 | Zhang et al (2013) Cancer Res. 4885–4897 | ||
| PT | SCID/Bg | No | No | No | F | No | CFP | 38 | 1 | 2.6 | 0 | 0 | 1 | 0 | 0 | nr | Zhang et al (2013) Cancer Res. 4885–4897 | ||
| PT | SCID/Bg | Pellet | Yes | No | F | No | CFP | 29 | 1 | 3.4 | 0 | 0 | 1 | 0 | 0 | nr | Zhang et al (2013) Cancer Res. 4885–4897 | ||
| PT | SCID/Bg | Pellet | No | Yes | F | No | IFP | 19 | 6 | 31.6 | nr | nr | nr | nr | nr | nr | Unpublished | ||
| PE/AS | SCID/Bg | Pellet | No | No | F | No | CFP | 4 | 4 | 100.0 | 2 | 0 | 2 | 100 | nd | 100 | Zhang et al (2013) Cancer Res. 4885–4897; Unpublished | ||
| PT | SCID/Bg | Pellet | No | No | F | Yes | CFP | 22 | 3 | 13.6 | nr | nr | nr | nr | nr | nr | Unpublished | ||
| PT | SCID/Bg | Pellet | No | Yes | F | Yes | CFP | 30 | 4 | 13.3 | nr | nr | nr | nr | nr | nr | Unpublished | ||
| PT | SCID/Bg | Pellet | No | Yes | F | Yes | IFP | 30 | 6 | 20.0 | nr | nr | nr | nr | nr | nr | Unpublished | ||
| PT | SCID/Bg | E2 Water | No | Yes | F | Yes | CFP | 30 | 3 | 10.0 | nr | nr | nr | nr | nr | nr | Unpublished | ||
| Bellvitge Institute for Biomedical Research IDIBELL (SPAIN) |
PT | NSG | No | No | No | F | No | CFP | 13 | 6 | 46.2 | 0 | 0 | 6 | NA | NA | 86 | Unpublished | |
| PT | NOD/SCID | Pellet | No | No | F | No | CFP | 40 | 2 | 5.0 | 2 | 0 | 0 | 7 | NA | 0 | Gomez-Miragaya et al (Submitted) | ||
| PE | Nude | No | No | Yes | D | No | IFP | 6 | 3 | 50.0 | 1 | 0 | 2 | 33 | NA | 66 | Gomez-Miragaya et al (Submitted) | ||
| British Columbia Cancer Agency (CANADA) |
PT | NSG/NRG | No | No | No | D/F | Yes for some | SQ-F | 76 | 40 | 44.7 | 13 | 6 | 19 | 23 | 22 | 55 | Eirew et al, Nature 2015; Unpublished. | |
| Ecole Polytechnique Federale De Lausanne (CH) |
PT | NSG | No | No | No | D | No | ID | 2 | 2 | 100.0 | 1 | 0 | 1 | 100 | NA | 100 | Sflomos et al. (2016) Cancer Cell 14;29(3):407–22 | |
| Institut Bergonié (FR) | PT | NSG | Pellet (ER+) | No | No | D | Yes | ID | 11 | 4 | 36.4 | 3 | 1f | NA | 38 | 33 | NA | Richard et al (2016) J Pathol DOI: 10.1002/path.4772 | |
| Institut Curie (FR) | PT/OM | Swiss Nude | E2 Water | No | No | F | No | SQ-S | 969 | 121 | 12.5 | 54 | 9 | 58 | 7 | 21 | 40 | Hatem et al. Oncotarget 2016 | |
| The Jackson Laboratory (JAX) (USA) | PT | NSG | Pellet | No | No | F | No | SQ-F | 220 | 29 | 13.2 | 1c | 1 | 25 | nr | nr | nr | Unpublished | |
| MD Anderson Cancer Center (USA) - Meric Bernstam |
nr | Nude | Pellet (ER+) | No | No | F | No | SQ-F | 47 | 13 | 27.7 | 6d | 0 | 7 | 18 | NA | 58 | McAuliffe et al (2015) PLOS One 10(9): e0136851. | |
| MD Anderson Cancer Center (USA) - Piwnica-Worms |
PT | NOD/SCID | No | Yes | Yes | D | No | IFP | 54 | 23 | 42.6 | 0 | 0 | 26 | NA | NA | 48 | Unpublishedb | |
| University of Colorado Anschutz Medical Campus (USA) |
PT/PE/AS PT/PE/AS |
NOD/SCID NSG |
Pellet Pellet |
No No |
Yes Yes |
F F |
No No |
IFP IFP |
14 95 |
4 21 |
28.6 22.1 |
3 9 |
0 1 |
1 11 |
nr 16 |
NA nr |
nr 57 |
Kabos et al (2012) Breast Cancer Res Treat. Sep;135(2):415-32 Kabos et al (2012) Breast Cancer Res Treat. Sep;135(2):415–32 |
|
| University of Manchester Institute of Cancer Sciences (UK) |
PT | NSG | E2 Water or Pellet |
No | Yes (D); No (F) |
D/F | No | SQ-F | 120 | 13 | 10.8 | 5 | 1 | 6 | 42 | 100 | 86 |
Eyre R., Alferez DG. et al. 2016 (in press Journal of Mammary Gland Biology and Neoplasia [JMGBN]) |
|
| PE | NSG | E2 Water or Pellet |
No | YES | D | No | SQ-F | 9 | 4 | 44.4 | 3 | 0 | 1 | 25 | NA | 14 | " | ||
| AS | NSG | E2 Water or Pellet |
No | YES | D | No | SQ-F | 15 | 3 | 20.0 | 4 | 0 | 0 | 33 | NA | NA | " | ||
| University of Michigan (USA) | PT | NSG | Pellet | No | Yes | F | Yes | IFP | 38 | 13 | 34.2 | 1 | 1 | 11e | 16 | 33 | 84 | Al Haj (2003) Nature; and unpublished | |
| PE | NOD/SCID | Pellet | yes | yes | D | nr | nr | nr | 5 | nr | 2 | 1 | 2 | nr | nr | nr | |||
| PT | NOD/SCID | Pellet | yes | yes | D/F | nr | nr | nr | 3 | nr | 1 | 0 | 2 | nr | nr | nr | |||
| University of Utah Huntsman - Cancer Institute (USA) |
PT/PE/AS | NOD/SCID | Beeswax Pellet (ER+) |
No | Yes (PE/AS); No (PT) |
D/F | No | CFP | 51 | 16 | 31.4 | 10 | 2 | 8 | 37 | 18 | 40 |
DeRose et al (2011) Nat Med. 17(11):1514–1521; DeRose et al (2013) Curr Prot Pharmacol. 4.23.1–14.23.43; Sikora et al. (2014) Cancer Res. 74(5):1463–1474. |
|
| Walter and Eliza Hall Institute of Medical Research (WEHI) (AU) |
PT/OM | NSG | Si-pellet | No | No | F | No | IFP | 298 | 59 | 20.8 | 20 | 6 | 36 | 10 | 19 | 56 |
Oakes et al (2012) PNAS 109(8):2766–71; Vaillant et al (2013) Cancer Cell 24(1):120–9; Nolan et al (2016) Nature Medicine Jun 20. doi: 10.1038/nm.4118; Unpublished |
|
| Washington University (USA) | PT/OM PT/OM |
NSG NSG |
No No |
Yes No |
No No |
F F |
No No |
CFP IFP |
74 313 |
12 56 |
16.2 17.9 |
3 26 |
1 3 |
9 31 |
nr nr |
nr nr |
nr nr |
Ding et al (2010) Nature 464(7291):999–1005; Li et al (2013) Cell Rep. 4(6):1116–30 ; Unpublished |
|
| 27.0 | 27.8 | 57.6 | |||||||||||||||||
| Average | |||||||||||||||||||
a
Defined as "stable" through passage 3
b
Defined as "stable" at passage 2
c
5 pending marker data
d
All low positivity
e
Includes 2 TNBC that converted to HER2+ upon passage